Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation	Yasuda T, Ueno T, Fukumura K, Yamato A, Ando M, Yamaguchi H, Soda M, Kawazu M, Sai E, Yamashita Y, Murata M, Kiyoi H, Naoe T and Mano H	Leukemia	2014，Feb.	国外
Secondary EML4-ALK-positive lung adenocarcinoma in a patient previously treated for acute lymphoblastic leukemia in childhood: a case report	Nakamura Y, Taniguchi H, Mizoguchi K, Ikeda T, Motoshima K, Yamaguchi H, Nagashima S, Nakatomi K, Soda M, Mano H and Kohno S	Jpn J Clin Oncol	2014，Jun.	国外

（注１）発表者氏名は、連名による発表の場合には、筆頭者を先頭にして全員を記載すること。

（注２）本様式はexcel形式にて作成し、甲が求める場合は別途電子データを納入すること。

<p align="center">学　会　等　発　表　実　績</p>

委託業務題目「急性骨髄性白血病におけるDNAメチル化によるMPO発現調節の検討」
機関名　長崎大学

１．学会等における口頭・ポスター発表

発表した成果（発表題目、口頭・ポスター発表の別）	発表者氏名	発表した場所（学会等名）	発表した時期	国内・外の別

２．学会誌・雑誌等における論文掲載

掲載した論文（発表題目）	発表者氏名	発表した場所（学会誌・雑誌等名）	発表した時期	国内・外の別
Expression of myeloperoxidase in acute myeloid leukemia blasts mirrors the distinct DNA methylation pattern involving the downregulation of DNA methyltransferase DNMT3B	Itonaga H, Imanishi D, Wong YF, Sato S, Ando K, Sawayama Y, Sasaki D, Tsuruda K, Hasegawa H, Imaizumi Y, Taguchi J, Tsushima H, Yoshida S, Fukushima T, Hata T, Moriuchi Y, Yanagihara K, Miyazaki Y.	Leukmia	2014, Jan.	国外
Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients	Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T	Leukemia	2014, Feb.	国外
Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome	Wong YF, Micklem CN, Taguchi M, Itonaga H, Sawayama Y, Imanishi D, Nishikawa S, Miyazaki Y, Jakt LM	Sten Cells Transl Med	2014, Jun.	国外
Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial	Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y, Emi N, Tamaki T, Gomyo H, Yamazaki E, Fujimaki K, Asou N, Matsuo K, Ohtake S, Miyazaki Y, Ohnishi K, Kobayashi Y, Naoe T	J Clin Oncol	2014, Sep.	国外
Lessons from the Atomic Bomb About Secondary MDS	Hata T, Imanishi D, Miyazaki Y	Curr Hematol Malig Rep	2014, Sep.	国外
Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient	Taguchi M, Imaizumi Y, Sasaki D, Higuchi T, Tsuruda K, Hasegawa H, Taguchi J, Sawayama Y, Imanishi D, Hata T, Yanagihara K, Yoshie O, Miyazaki Y	Ann Hematol	2014, Oct.	国外

Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome	Iriyama N, Asou N, Miyazaki Y, Yamaguchi S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y, Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K, Kobayashi Y, Naoe T	Ann Hematol	2014, Jan.	国外

（注１）発表者氏名は、連名による発表の場合には、筆頭者を先頭にして全員を記載すること。

（注２）本様式はexcel形式にて作成し、甲が求める場合は別途電子データを納入すること。

様式第１９

<div align="center">学 会 等 発 表 実 績</div>

委託業務題目「ヒストン脱アセチル化酵素阻害薬romidepsinに対する耐性機序の解析」
機関名　自治医科大学

１．学会等における口頭・ポスター発表

発表した成果（発表題目、口頭・ポスター発表の別）	発表者氏名	発表した場所（学会等名）	発表した時期	国内・外の別

２．学会誌・雑誌等における論文掲載

掲載した論文（発表題目）	発表者氏名	発表した場所（学会誌・雑誌等名）	発表した時期	国内・外の別
Mechanisms of resistance to azacitidine in human leukemia cell lines	Sripayap P, Nagai T, Uesawa M, Kobayashi H, Tsukahara T, Ohmine K, Muroi K & Ozawa K	Exp Hematol	2014, Nov.	国外
Leukemia cells directly phagocytose blood cells in AML-associated hemophagocytic lymphohistiocytosis	Hatano K, Nagai T, Matsuyama T, Sakaguchi Y, Fujiwara S, Oh I, Muroi K & Ozawa K	Acta Haematologica	2014, Sep.	国外
Hemoperfusion for Hodgkin Lymphoma-associated Hemophagocytic Lymphohistiocytosis	Tatara R, Sato M, Fujiwara S, Oh I, Muro K, Ozawa K & Nagai T	Internal Med	2014, Apr.	国外
Intrathecal Administration of High-Titer Cytomegalovirus Immunoglobulin for Cytomegalovirus Meningitis	Fujiwara S, Muroi K, Tatara R, Ohmine K, Matsuyama T, Mori M, Nagai T & Ozawa K	Case Reports in Hematol	2014, May.	国外
The bone marrow hematopoietic microenvironment is impaired in iron-overloaded mice	Okabe H, Suzuki T, Uehara E, Ueda M, Nagai T & Ozawa K	Eur J Haematol	2014, Mar.	国外

Clinical features of de novo CD25-positive follicular lymphoma	Fujiwara S, Muroi K, Tatara R, Matsuyama T, Ohmine K, Suzuki T, Mori M, Nagai T, Tanaka A & Ozawa K	Leuk Lymphoma	2014, Feb.	国外
Two granulocytic regions in bone marrow with eosinophilia evaluated by flow cytometry	Muroi K, Fujiwara S, Tatara R, Sato K, Oh I, Ohmine K, Suzuki T, Nagai T, Ozawa K & Kanda Y	J Clin Exp Hematop	2014, Oct.	国外
Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes	Suzuki T, Oh I, Ohmine K, Meguro A, Mori M, Fujiwara S, Yamamoto C, Nagai T & Ozawa K	Int J Hematol	2014, Nov.	国外

（注１）発表者氏名は、連名による発表の場合には、筆頭者を先頭にして全員を記載すること。

（注２）本様式はexcel形式にて作成し、甲が求める場合は別途電子データを納入すること。

様式第１９

<p style="text-align:center">学 会 等 発 表 実 績</p>

委託業務題目「白血球に発現するＧ蛋白質共役型受容体」
機関名　岡山理科大学

１．学会等における口頭・ポスター発表

発表した成果（発表題目、口頭・ポスター発表の別）	発表者氏名	発表した場所（学会等名）	発表した時期	国内・外の別

２．学会誌・雑誌等における論文掲載

掲載した論文（発表題目）	発表者氏名	発表した場所（学会誌・雑誌等名）	発表した時期	国内・外の別
Interplay between CXCR2 and BLT1 Facilitates Neutrophil Infiltration and Resultant Keratinocyte Activation in a Murine Model of Imiquimod-Induced Psoriasis	Sumida, H., Yanagida, K., Kita, Y., Abe, J., Matsushima, K., Nakamura, M., Ishii, S., Sato, S., and Shimizu, T.	J Immunol.	2014, Feb.	国外
Visualization of the pH-dependent dynamic distribution of G2A in living cells.	Lan, W., Yamaguchi, S., Yamamoto, T., Yamahira, S., Tan, M., Murakami, N., Zhang, J., Nakamura, M., and Nagamune, T.	The FASEB J.	2014, May	国外

（注１）発表者氏名は、連名による発表の場合には、筆頭者を先頭にして全員を記載すること。

（注２）本様式はexcel形式にて作成し、甲が求める場合は別途電子データを納入すること。

<div align="center">

学 会 等 発 表 実 績

</div>

委託業務題目「白血病関連変異遺伝子の機能的意義の解明」
機関名　愛知県がんセンター

１．学会等における口頭・ポスター発表

発表した成果（発表題目、口頭・ポスター発表の別）	発表者氏名	発表した場所（学会等名）	発表した時期	国内・外の別

２．学会誌・雑誌等における論文掲載

掲載した論文（発表題目）	発表者氏名	発表した場所（学会誌・雑誌等名）	発表した時期	国内・外の別
Molecular Characterization of Chronic-type Adult T-cell Leukemia/Lymphoma.	Yoshida N, Karube K, Utsunomiya A, Tsukasaki K, Imaizumi Y, Taira N, Uike N, Umino A, Arita K, Suguro M, Tsuzuki S, Kinoshita T, Ohshima K, Seto M	Cancer Res.	2014, Oct.	国外

（注１）発表者氏名は、連名による発表の場合には、筆頭者を先頭にして全員を記載すること。

（注２）本様式はexcel形式にて作成し、甲が求める場合は別途電子データを納入すること。

Leukemic evolution of donor-derived cells harboring *IDH2* and *DNMT3A* mutations after allogeneic stem cell transplantation

Although allogeneic stem cell transplantation is effective for the treatment of leukemia with poor prognosis, some such treated individuals experience disease relapse at various times after transplantation. Chimerism analysis of the relapsed disease has revealed infrequent cases in which the malignant cells originate from the donor and not from the initial leukemic clones.[1,2] Such donor cell leukemia (DCL) is often refractory to further treatment, with a mean overall survival for the affected patients of only 32.8 months.[2]

We recently described a 47-year-old Japanese man with acute myeloid leukemia (AML) who underwent a transplantation of peripheral blood stem cells (PBSCs) from his HLA-matched brother.[3] Although the allogeneic transplantation was successful, AML again became apparent in the patient 27 months later and chimerism analysis revealed that the leukemia was DCL. Genomic DNA was isolated and subjected to whole-exome sequencing from specimens of the initial AML (containing 70% myeloblasts, referred to as sample P1), the first complete remission after chemotherapy (sample P2), the first relapse (containing 24% myeloblasts; sample P3), donor PBSCs (sample D1), DCL at 27 months after allogeneic transplantation (containing 6% myeloblasts, sample D2) and DCL at 36 months after transplantation (containing 71% myeloblasts, sample D3).

Exome sequencing yielded a total of ~84.7 million, ~31.6 million, ~73.5 million, ~44.3 million and ~53.2 million unique, high-quality, paired-end reads for samples P1, P2, P3, D1 and D3,

respectively (Supplementary Information). Although chimerism analysis for short tandem repeats had indicated that D3 was derived from D1 clones,[3] we further examined this possibility in a genome-wide manner. As demonstrated in Supplementary Figure 1a, the allele frequency of single-nucleotide polymorphisms (SNPs) detected in our data sets was highly concordant between P1 and P2 (Pearson's correlation coefficient (*r*) of 0.978) as well as between P1 and P3 (*r* = 0.986), suggesting that these three samples originate from a single individual. However, as expected, the concordance dropped substantially for the P1 and D3 pair (*r* = 0.628). In contrast, the concordance between D1 and D3 was high (*r* = 0.983), suggesting that the relapsed leukemia after transplantation was indeed derived from the donor cell. Of note, the allele frequency of SNPs showed only a low level of concordance (*r* = 0.285) between P1 and a cell line (KCL22)[4] derived from an unrelated Japanese patient with chronic myeloid leukemia (Supplementary Figure 1b). The correlation coefficient of 0.628 for P1 and D3 thus indicated that the patient and donor siblings share a substantial number of SNPs.

We next searched for somatic nonsynonymous mutations among the leukemic samples. For P1 and P3, we used P2 as a paired normal control. Given that D3 was shown to be derived from D1, we used the latter as the germline control for the former. Through our computational pipeline (Supplementary Information), nine missense mutations and two out-of-frame insertions/deletions (indels) were detected for P1, two missense mutations for P3 and nine missense mutations and one out-of-frame indel for D3 (Table 1). As described previously,[3] a 4-bp deletion of *CEBPA* was present in the initial AML but absent from the DCL. Similarly,

Table 1. Confirmed somatic mutations in the specimens analyzed

Specimen	Gene symbol	GenBank accession no.	Nucleotide change	Amino-acid change	Mutation ratio (%)				
					P1	P2	P3	D1	D3
P1	ACSL5	NM_016234	c.280G>A	p.V94I	40.6	0.0	30.6	0.0	0.0
	ANO4	NM_178826	c.2441C>T	p.S814L	42.3	0.0	16.7	0.0	0.0
	APOB	NM_000384	c.9175C>T	p.R3059C	32.8	0.0	7.4	0.0	0.0
	BANK1	NM_017935	c.222C>G	p.N74K	36.4	0.0	9.2	0.0	0.0
	CCDC88C	NM_001080414	c.3748G>A	p.E1250K	36.4	0.0	0.0	0.0	0.0
	FAM178B	NM_001122646	c.81G>A	p.M27I	41.2	0.0	25.0	0.0	0.0
	GABRB2	NM_021911	c.1009C>T	p.R337C	44.8	0.0	14.5	0.0	0.0
	JAK3	NM_000215	c.2570T>C	p.L857P	40.8	0.0	0.0	0.0	0.0
	SPATA31D1	NM_001001670	c.3793C>T	p.R1265C	36.6	0.0	6.7	0.0	0.0
	CEBPA	NM_004364	c.319_322delGACT	p.D107Tfs	63.6	0.0	10.0	0.0	0.0
	STAG2	NM_001042750	c.219_220insCG	p.H73Rfs	100.0	0.0	27.6	0.0	0.0
P3	ACSL5	NM_016234	c.280G>A	p.V94I	40.6	0.0	30.6	0.0	0.0
	NTNG2	NM_032536	c.1348G>T	p.G450C	0.0	0.0	37.5	0.0	0.0
D3	CCDC168	NM_001146197	c.11761G>C	p.D3921H	0.0	0.0	0.0	0.0	55.6
	GAL3ST1	NM_004861	c.1086G>T	p.M362I	0.0	0.0	0.0	0.0	32.6
	IDH2	NM_002168	c.419G>A	p.R140Q	0.0	0.0	0.0	7.1	50.0
	MYO7B	NM_001080527	c.635G>A	p.R212H	0.0	0.0	0.0	0.0	45.8
	NFATC1	NM_172390	c.736G>A	p.V246I	0.0	0.0	0.0	0.0	48.6
	PSMB8	NM_004159	c.637C>T	p.P213S	0.0	0.0	0.0	0.0	40.9
	TCAIM	NM_173826	c.668C>G	p.S223C	0.0	0.0	0.0	0.0	70.0
	TMEM132D	NM_133448	c.481G>A	p.A161T	0.0	0.0	0.0	0.0	35.3
	UBA2	NM_005499	c.419G>A	p.G140E	0.0	0.0	0.0	0.0	47.4
	DNMT3A	NM_153759	c.449delT	p.V150Gfs	0.0	0.0	0.0	8.7	61.1
	NRAS[a]	NM_002524	c.38G>A	p.G13D	0.0	0.0	0.0	0.0	18.4

[a]Below the threshold in the initial screening.

none of the identified somatic mutations were shared between the initial AML and DCL, providing further support for the distinct nature of the two leukemias.

Given that P3 contains only 24% myeloblasts, our computational pipeline could not accurately detect all of the associated somatic mutations. Indeed, most of the somatic mutations found in P1 (such as those in ANO4, APOB, BANK1, STAG2 and CEBPA) were still present in P3 at lower frequencies (Table 1) but were not isolated in our pipeline analysis for P3. Lowering the threshold for somatic calls, however, increased the number of pseudopositive mutations in all specimens. We therefore applied the 30% threshold for mutation calls to all analyses. Of note, our data still indicate that P3 is not completely identical to P1. Nonsynonymous mutations of CCDC88C and JAK3 detected in P1 were thus absent in P3, whereas a mutation of NTNG2 was newly apparent in P3, suggestive of a clonal evolution in P3 divergent from the original P1 clones.

Surprisingly, whereas most somatic mutations detected in D3 were not present in D1, our results suggested that IDH2(R140Q) and DNMT3A(V150Gfs) were already present in the healthy donor at a low frequency (Table 1). Polymerase chain reaction (PCR)-based cloning of the genomic fragments and Sanger sequencing for IDH2 and DNMT3A from D1 indeed confirmed the presence of the corresponding mutations in 2 (2.3%) out of 87 DNA clones and 1 (1.1%) out of 93 clones, respectively (Supplementary Figure 2). Furthermore, although the mutation rate (18.4%) was below the threshold of the present study, the oncogenic mutation NRAS(G13D)[5] in D3 (Table 1) was confirmed by Sanger sequencing of the corresponding genomic DNA (Supplementary Figure 2).

We then verified these infrequent mutations by sequencing the corresponding DNA fragments at extra-high coverage (hundreds of thousand times) with the use of a next-generation sequencer. The D2 sample, which contains only 6% myeloblasts, was also examined in this analysis. We confirmed that 1.6% (5.96×10^3 mutant reads out of 3.67×10^5 total reads at the corresponding nucleotide position) and 2.1% (1.24×10^4 out of 6.01×10^5 reads) of D1 cells already harbored the IDH2(R140Q) and DNMT3A(V150Gfs) mutations, respectively (Figure 1a). These mutations were not detected in the primary AML (P1 to P3). Whereas the NRAS mutation was not detected in D1, it became apparent in D2 and D3 at a frequency similar to that of the IDH2 mutation. In addition, the JAK3 mutation present in P1 was no longer evident at the relapsed stage P3.

On the basis of the genetic mutation profiles identified in the present case, we propose the following scheme for disease progression (Figure 1b). Given the high frequency of STAG2 and CEBPA mutations in the primary AML, the 2-bp insertion in STAG2 on the X chromosome (with there being only one copy of STAG2 per cell in the male patient) as well as the heterozygous 4-bp deletion in CEBPA may characterize the founding clone of the original leukemia, with subsets of this clone subsequently acquiring additional oncogenic hits such as JAK3(L857P). The disappearance of JAK3 and CCDC88C mutations in P3 suggests that the leukemic subclones harboring these mutations were sensitive to the initial chemotherapy.

The molecular pathogenesis of DCL has been unclear and may differ among cases. For instance, germline predisposition to cancer, such as the Li-Fraumeni syndrome or Bloom syndrome, may be shared between recipients and related donors.[6] However, in the present case, mutations in IDH2 and DNMT3A were detected only in the donor, not in the primary AML, rendering this scenario unlikely. Alternatively, occult leukemia may already be present in the donor blood system and is inadvertently transmitted to the recipient.[7] In such cases, however, leukemia usually emerges in the donor soon after transplantation. Our donor, in contrast, has not developed any hematologic malignancy at 10 years after the donation of his PBSCs.

Figure 1. Genomic analysis of AML samples and donor PBSCs. (**a**) Genomic mutations corresponding to CEBPA(D107Tfs), STAG2(H73Rfs), JAK3(L857P), IDH2(R140Q), DNMT3A(V150Gfs) and NRAS(G13D) were examined by targeted deep sequencing in genomic DNA prepared from samples P1, P2, P3, D1, D2 and D3. The ratio of mutant reads to all reads at the corresponding position is shown as a percentage, with mutation frequencies of <0.1% being considered as 0.1% in the graph. The percentage of myeloblasts in each sample is indicated below the graph. (**b**) Founding clones of the primary AML harbored nonsynonymous mutations of STAG2 and CEBPA and gave rise to subclones harboring a JAK3 mutation. Whereas the latter cell population was sensitive to the initial chemotherapy, a subclone positive for an NTNG2 mutation emerged from the former population and gave rise to relapse. All of these leukemic clones were successfully eradicated by peripheral blood stem cell transplantation (PBSCT). PBSCs of the donor, however, contained a small clonal population of cells positive for IDH2 and DNMT3A mutations that eventually gave rise to AML on acquisition of additional mutations including NRAS(G13D).

Our present data therefore strongly suggest that apparently healthy individuals may harbor preleukemic subclones in their blood system (Figure 1b). Indeed, somatic mutations of TET2 and DNMT3A were recently identified in clonal blood cells from one healthy elderly individual.[8] Furthermore, the IDH2 and DNMT3A mutations identified in the present study may have had a specific role in the initiation of leukemia, given that mutations in the epigenetic modifiers including TET1/2, IDH1/2 and DNMT3A have been identified as early genetic events in AML progression.[9,10] Such mutations are indeed among the most frequently detected somatic alterations in AML.[11] These observations raise an important concern as to how 'appropriate' donors should be chosen, especially given that the incidence of DCL is increasing with the prevalence of molecular analysis for donor/recipient chimerism.[2] Prospective studies of whether and how examination of preleukemic subclones should be incorporated into the donor selection process for stem cell transplantation are thus warranted.

Furthermore, in our case, the oncogenic mutation NRAS(G13D) was likely a driver for leukemia progression, given that the frequency of this mutation was almost identical to that of the IDH2 mutation in the D2 and D3 specimens. In contrast to the absence of leukemia in the donor, DCL rapidly developed in the recipient after transplantation in association with the accumulation of additional genetic hits, possibly as a result of a growth-promoting condition of the bone marrow after transplantation and due to a

defective immune surveillance resulting from the immunosuppressive treatment to control graft-versus-host disease.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

T Yasuda[1,2], T Ueno[1], K Fukumura[1], A Yamato[1], M Ando[1],
H Yamaguchi[1], M Soda[1], M Kawazu[3], E Sai[3], Y Yamashita[3],
M Murata[2], H Kiyoi[2], T Naoe[2,4] and H Mano[1,5]
[1]Department of Cellular Signaling, Graduate School of Medicine,
The University of Tokyo, Tokyo, Japan;
[2]Department of Hematology and Oncology, Graduate School of
Medicine, Nagoya University, Aichi, Japan;
[3]Department of Medical Genomics, Graduate School of Medicine, The
University of Tokyo, Tokyo, Japan;
[4]National Hospital Organization Nagoya Medical Center, Aichi, Japan and
[5]CREST, Japan Science and Technology Agency, Saitama, Japan
E-mail: hmano@m.u-tokyo.ac.jp

REFERENCES

1 Fialkow PJ, Thomas ED, Bryant JI, Neiman PE. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet 1971; 1: 251–255.
2 Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant 2011; 17: 771–789.
3 Murata M, Ishikawa Y, Ohashi H, Terakura S, Ozeki K, Kiyoi H et al. Donor cell leukemia after allogeneic peripheral blood stem cell transplantation: a case report and literature review. Int J Hematol 2008; 88: 111–115.
4 Kubonishi I, Miyoshi I. Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1983; 1: 105–117.
5 Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012; 72: 2457–2467.
6 Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001; 20: 4621–4628.
7 Sala-Torra O, Hanna C, Loken MR, Flowers ME, Maris M, Ladne PA et al. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 511–517.
8 Busque L, Patel JP, Figueroa ME, Vasanthakumar A, Provost S, Hamilou Z et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179–1181.
9 Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012; 4: 149ra118.
10 Wakita S, Yamaguchi H, Omori I, Terada K, Ueda T, Manabe E et al. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia 2013; 27: 1044–1052.
11 Network TCGAR. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)

Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of *MLL* rearrangements

Acute lymphoblastic leukemia (ALL) in infants less than 1 year of age is rare and the biological features are different from ALL in older children.[1] Infant ALL is characterized by a high frequency of rearrangements of the *MLL* gene (*MLL*-R) and heterogeneous outcome. However overall, their event-free survival (EFS) is much worse than older children with ALL.[1–5] A large collaborative trial, Interfant-99, demonstrated improved outcome, while characterizing definitively the independent prognostic variables in infant ALL.[6] While cytogenetic data are reported within individual infant ALL clinical trials, the numbers are typically small and many reports are less detailed for those patients without *MLL* gene rearrangements (*MLL*-G). However, it was previously suggested that *MLL*-G had an important predictive influence on outcome.[7,8] These observations were later confirmed in Interfant-99,[6] in which *MLL*-G patients showed a threefold reduced risk of an event compared with *MLL*-R patients, although all *MLL*-G patients were grouped together into a single category. To better understand the association of different chromosomal abnormalities and outcome among *MLL*-G infants, here we have carried out detailed cytogenetic investigation of two infant ALL trials: Interfant-99 and Children's Oncology Group (COG)-P9407.

Patients were 365 days old or less with newly diagnosed ALL without a rearrangement of the *MLL* gene enrolled to

Interfant-99 (May 1999–December 2005; n = 110) and COG-P9407 (June 1996–October 2006; n = 52).[6,9] Individual study groups obtained ethical approval, and treating physicians obtained informed consent from parents or guardians. The presence of *MLL* gene rearrangements was excluded using fluorescence *in situ* hybridization (FISH), reverse transcription (RT)-PCR and/or Southern blotting, as previously reported.[6] Each national study group provided patient data, including cytogenetics, FISH and molecular results. EFS and overall survival (OS) were calculated from the date of trial enrolment to the date of the first event (induction failure, relapse, second malignancy or death) or last follow-up. Median follow-up time was 7 years.

Among 162 *MLL*-G patients, no cytogenetic data were available for 34 (21%), resulting in a success rate of 79%. An abnormal karyotype was detected in 90/128 (70%) patients with a successful cytogenetic result (Supplementary Table 1) with the remainder classified as normal based on the presence of at least 10 (but usually 20) normal metaphases. They were categorized according to cytogenetic risk group as previously defined for childhood ALL.[10] Compared with childhood ALL (1–18 years) using data from the UKALL97/99 treatment trial,[10] the frequency of good risk cytogenetic abnormalities among *MLL*-G infants was significantly lower (12 vs 60%, P < 0.01), whereas the frequency of poor risk abnormalities (excluding *MLL* translocations) was similar (8 vs 10%). Although *ETV6–RUNX1* fusion is present in 25% of childhood ALL, we found no *ETV6–RUNX1* cases among the 75 patients tested by FISH or RT-PCR. High hyperdiploidy (HeH) was the most